GPR25 Antibody

What is GPR25 and what are its key structural and functional characteristics?

GPR25 is an intronless, orphan G protein-coupled receptor with a canonical protein length of 361 amino acid residues and a mass of 38.8 kDa in humans . It belongs to the G-protein coupled receptor 1 family and shares highest homology with GPR15, angiotensin II type 1A receptor, and somatostatin receptor 5 .

Key characteristics include:

• Subcellular localization in the cell membrane

• Expression on platelet surfaces and in immune cells

• Role in immune regulation and inflammatory responses

• Linkage to arterial stiffness

• Cleavage at amino acid residues 315-316 by HIV-1 protease

• Potential involvement in thrombosis mechanisms

GPR25 remains classified as an orphan receptor, meaning its endogenous ligand has not yet been identified . Gene orthologs have been reported in mouse, rat, bovine, and chimpanzee species, indicating evolutionary conservation .

What applications are GPR25 antibodies most commonly used for in research?

GPR25 antibodies are employed across multiple experimental platforms to investigate expression, localization, and function of this receptor. The primary applications include:

These antibodies can detect GPR25 in various experimental contexts, allowing researchers to investigate expression patterns, protein interactions, and potential roles in disease pathogenesis .

How should GPR25 antibodies be validated before use in experimental procedures?

Proper validation of GPR25 antibodies is essential for generating reliable research data. A comprehensive validation approach includes:

Positive controls:

• Transfected cell lines overexpressing GPR25 (e.g., HEK293 cells stably expressing GPR25)

• Tissues known to express GPR25 (e.g., small intestine, platelets)

Negative controls:

• Mock-transfected cells or non-transfected parental cell lines

• Tissues from GPR25 knockout models (if available)

• Antibody pre-absorption with immunizing peptide

Validation techniques:

• Western blot analysis confirming expected molecular weight (38.8-39 kDa)

• Immunohistochemistry with appropriate tissue sections

• Flow cytometry for cell surface expression

• Functional assays that correlate with receptor expression levels

For example, the non-phospho-GPR25 receptor antibody has been validated using both transfected HEK293 cells and small intestine sections, confirming specificity before application in experimental procedures .

What is known about GPR25 expression patterns in human tissues and cells?

GPR25 demonstrates a specific expression pattern across human tissues and cell types:

Cell types with confirmed GPR25 expression:

• Platelets (surface expression confirmed by monoclonal antibodies)

• Various white blood cell populations (detected at mRNA level)

• Small intestine epithelial cells (detected by immunohistochemistry)

While comprehensive expression mapping remains incomplete, GPR25 transcripts have been detected in human immune cells, suggesting potential immunomodulatory functions . The receptor's presence on platelets is particularly significant given the association between a GPR25 mutation (c.764G>T:p.G255V) and a hereditary thrombocytopenia with thrombosis phenotype .

Researchers investigating GPR25 expression should consider both protein-level detection methods (immunohistochemistry, flow cytometry) and transcript analysis (RT-PCR, RNA-seq) for comprehensive profiling.

What experimental approaches can differentiate between phosphorylated and non-phosphorylated forms of GPR25?

Distinguishing between phosphorylated and non-phosphorylated GPR25 provides insights into receptor activation and signaling dynamics. Several approaches can be employed:

Antibody-based detection:

• Use of phosphorylation-independent antibodies (e.g., 7TM0095N) that recognize total GPR25 regardless of phosphorylation status

• Phospho-specific antibodies targeting known phosphorylation sites (T152, S159, S174, Y177, S256)

Analytical techniques:

• Phos-tag™ SDS-PAGE: This modified gel electrophoresis technique can separate phosphorylated from non-phosphorylated proteins by mobility shift

• 2D gel electrophoresis: Combining isoelectric focusing with SDS-PAGE to separate proteins based on charge (affected by phosphorylation) and mass

• Mass spectrometry: For identification and quantification of specific phosphorylation sites

Experimental design considerations:

• Include phosphatase treatments as controls to demonstrate specificity

• Compare receptor phosphorylation before and after potential ligand stimulation

• Consider kinase inhibitor treatments to identify kinases involved in GPR25 phosphorylation

Understanding the phosphorylation state provides crucial insights into GPR25 regulation, as G protein-coupled receptors typically undergo phosphorylation during desensitization and internalization processes.

How can GPR25 antibodies be applied to investigate the relationship between GPR25 mutations and thrombotic disorders?

The identification of a heterozygous mutation (c.764G>T:p.G255V) in GPR25 linked to hereditary thrombocytopenia with thrombosis provides a compelling research direction . To investigate this relationship:

Patient sample analysis:

• Screen patient platelets with anti-GPR25 antibodies to assess expression levels via flow cytometry or Western blot

• Compare GPR25 localization patterns between normal and patient platelets using immunofluorescence microscopy

• Perform co-immunoprecipitation studies to examine altered protein interactions in mutant GPR25

Functional studies:

• Platelet aggregation assays comparing wild-type and mutant GPR25 responses to agonists like ADP, as enhanced ADP-induced aggregation was observed in patient platelets

• Annexin V binding assays to assess phosphatidylserine exposure, which was increased in patient platelets after thrombin+collagen or A23187 stimulation

• Calcium mobilization studies to evaluate signaling alterations

Model systems:

• Generate cell lines expressing wild-type or mutant GPR25 (G255V)

• Create transgenic mouse models harboring the equivalent mutation

• Use CRISPR/Cas9 to introduce the mutation into megakaryocytic cell lines

These approaches can illuminate how GPR25 mutations affect platelet function and contribute to thrombotic tendency, potentially informing novel therapeutic strategies for inherited thrombocytopenias.

What are the optimal methods for using GPR25 antibodies in immunohistochemical applications?

Successful immunohistochemical detection of GPR25 requires attention to several technical parameters:

Tissue preparation:

• Fixation: 10% neutral buffered formalin for 24-48 hours is standard, though antigen retrieval will be necessary

• Processing: Standard paraffin embedding with 4-6 μm section thickness

• Antigen retrieval: Heat-induced epitope retrieval in citric acid buffer (pH 6.0) using microwave treatment

Staining protocol:

• Deparaffinize sections in xylene and rehydrate through graded alcohols

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Apply GPR25 antibody at optimized dilution (typically 1:100 for IHC)

• Incubate at 4°C overnight in a humidified chamber

• Apply biotinylated secondary antibody followed by avidin-biotin complex

• Develop with 3,3-diaminobenzidine (DAB)-glucose oxidase

• Counterstain lightly with hematoxylin

Controls and validation:

• Include positive control tissue (small intestine has shown reliable GPR25 expression)

• Include negative controls by omitting primary antibody

• Consider peptide competition assays to confirm specificity

An optimized protocol similar to this has successfully detected GPR25 in small intestine tissue sections, revealing specific cellular and subcellular distribution patterns .

What methodological approaches can enhance detection sensitivity when working with low GPR25 expression levels?

When investigating tissues or cells with low GPR25 expression, several methodological refinements can improve detection sensitivity:

Western blot enhancements:

• Increase protein loading (50-100 μg total protein)

• Use high-sensitivity chemiluminescent substrates

• Employ membrane concentration techniques like immunoprecipitation before Western blotting

• Utilize signal amplification systems (e.g., biotin-streptavidin)

• Consider specialized low-background PVDF membranes

Immunohistochemistry/immunofluorescence optimization:

• Implement tyramide signal amplification (TSA) systems

• Extend primary antibody incubation time (overnight at 4°C)

• Optimize antigen retrieval methods systematically

• Use high-affinity detection systems (e.g., polymer-based detection)

• Consider confocal microscopy for improved signal-to-noise ratio

Transcript analysis complementation:

• Employ quantitative RT-PCR with probe-based detection

• Use RNA in situ hybridization techniques like RNAscope to localize transcripts

• Consider digital droplet PCR for absolute quantification of low-abundance transcripts

These approaches can be particularly valuable when studying GPR25 in primary cells or tissues where expression may be physiologically low, or when examining how expression changes in response to experimental manipulations.

How can GPR25 antibodies be employed to investigate potential roles in immune regulation and inflammatory responses?

GPR25 has been implicated in immune regulation and inflammatory processes . To investigate these roles:

Expression analysis in immune contexts:

• Examine GPR25 expression across immune cell subsets using flow cytometry with anti-GPR25 antibodies

• Analyze expression changes during immune cell activation using Western blot or flow cytometry

• Perform immunohistochemistry on inflammatory tissues to assess GPR25-expressing cells

Functional investigations:

• Use neutralizing anti-GPR25 antibodies to block receptor function in immune cell cultures

• Perform co-immunoprecipitation to identify GPR25 interaction partners in immune cells

• Assess immune cell migration, cytokine production, and activation markers after GPR25 modulation

Disease models:

• Analyze GPR25 expression in tissues from inflammatory disease models

• Compare GPR25 localization and phosphorylation status between healthy and diseased tissues

• Correlate GPR25 expression levels with inflammatory markers

For instance, researchers could isolate primary monocytes or macrophages, stimulate them with inflammatory mediators (LPS, TNF-α, IL-1β), and assess changes in GPR25 expression and phosphorylation using Western blot with appropriate anti-GPR25 antibodies. This approach would provide insights into how inflammatory conditions regulate this receptor.

What are the current technical limitations of available GPR25 antibodies and how might they be addressed?

Current technical limitations of GPR25 antibodies present several challenges that researchers should consider:

Specificity concerns:

• Cross-reactivity with related GPCRs due to sequence homology with receptors like GPR15

• Non-specific binding in certain tissues or under specific fixation conditions

• Variable performance across different experimental platforms

Methodological limitations:

• Limited availability of monoclonal antibodies for many epitopes

• Few phospho-specific antibodies for studying activation status

• Incomplete validation across all potential applications

• Variable lot-to-lot performance with polyclonal antibodies

Addressing these limitations:

• Expanded validation: Comprehensive cross-reactivity testing against related GPCRs

• Advanced antibody engineering: Development of recombinant antibodies with defined epitope targeting

• Alternative approaches: Complement antibody-based detection with CRISPR-Cas9 tagging of endogenous GPR25

• Comparative testing: Benchmark multiple commercially available antibodies in parallel

• Custom development: Generation of application-specific antibodies (e.g., conformation-specific antibodies that distinguish active vs. inactive states)

Researchers should implement robust controls in all experiments, including:

• GPR25 knockout or knockdown samples when available

• Peptide competition assays to confirm binding specificity

• Validation in model systems with controlled GPR25 expression

As GPR25 research advances, developing more specific tools will be crucial for accurately defining its roles in normal physiology and disease processes.